Navigation Links
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Date:8/29/2010

nts a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that Sanofi-Aventis had made an approach to acquire Genzyme.  Based on the analysts' consensus estimates, this represents a multiple of 36 times 2010 EPS and 20 times 2011 EPS, which takes into account the expected recovery of Genzyme's performance in 2011.

We believe that now is the right time for you and the Genzyme Board to consider a potential transaction that maximizes value for Genzyme's shareholders.  Genzyme has underperformed its peers for a number of years.  It continues to face several significant and well-documented challenges that were discussed thoroughly during this year's proxy campaign, and which Genzyme recently disclosed will take three to four years to resolve.  An acquisition by Sanofi-Aventis would not only position Genzyme to overcome these challenges quickly and successfully by applying Sanofi-Aventis' global resources and expertise to help realize Genzyme's business strategy, but also deliver near-term compelling value to Genzyme's shareholders that takes into account the company's future upside potential.

As I explained in my July 29 letter, the proposed transaction would provide several key benefits to Genzyme, its shareholders, employees and the patients and physicians it serves, including:

  • Achievement of Genzyme's Vision:  Sanofi-Aventis would put its full resources behind Genzyme to invest in developing new treatments, enhance penetration in existing markets and further expand into emerging markets.  Genzyme would be able to leverage Sanofi-Aventis' strong global footprint and its manufacturing expertise in order to address Genzyme's manufacturing issues.

  • Center of Excellence:  Sanofi-Aventis already recognizes the strategic importance of the greater Boston area as evidenced by the establishment of Sanofi-Aventis'
    '/>"/>

  • SOURCE Sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    3. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
    4. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
    5. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
    6. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
    7. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
    8. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
    9. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
    10. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    11. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... -- According to a new market research ... Radiography, Ultrasound, Computed & Optical Coherence Tomography, MRI, PET/CT ... Neurology) - Global Forecast to 2020", the Global Veterinary ... by 2020 growing at a CAGR of 6.6% during ... 240 Tables and 44 F igures spread through ...
    (Date:9/2/2015)... , Sept. 2, 2015 Boston Scientific Corporation ... 2015 Morgan Stanley Global Healthcare Conference on September 17, in ... Mike Mahoney , chief executive officer, and Dan Brennan ... in a 30-minute question and answer session regarding the company ... A live webcast of the question and answer ...
    (Date:9/2/2015)... Sept. 2, 2015  MEI Pharma, Inc. (Nasdaq: ... development of novel therapies for cancer, today announced results ... Logo - http://photos.prnewswire.com/prnh/20140805/133834 ... am quite pleased with how the Company is positioned ... , Ph.D., President and Chief Executive Officer of MEI ...
    Breaking Medicine Technology:Veterinary Imaging Market Worth USD 2.8 Billion by 2020 2Veterinary Imaging Market Worth USD 2.8 Billion by 2020 3Veterinary Imaging Market Worth USD 2.8 Billion by 2020 4Veterinary Imaging Market Worth USD 2.8 Billion by 2020 5Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference 2MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7
    ... Dendreon Corporation (Nasdaq:,DNDN) today will present a ... an investigational active cellular immunotherapy, at the,Chemotherapy Foundation ... the data from two clinical trials, highlights the ... in patients with,HER2/neu-positive cancer who have failed standard ...
    ... 6 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular disease, announced today ... to discuss results of the,VIA-2291 Phase 2 acute ... at the American Heart Association (AHA) Scientific,Sessions 2008 ...
    Cached Medicine Technology:Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 2Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 3Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 4VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA 2
    (Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Amada Senior Care, premier provider ... Kansas – its Johnson County location. Amada franchise partners Mike and Mell ... registered nurse background and spent over 20 years in medical device sales while Mell ...
    (Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an industry leader specializing ... house in the world, selling more than 100,000 pieces of medical equipment every ...
    (Date:9/2/2015)... Utah (PRWEB) , ... September 02, 2015 , ... On ... Utah to attend doTERRA’s annual convention, the largest single-company convention to date for the ... Advocates and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , ... combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing ...
    Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4
    ... venom of the brown recluse spider, researchers at the University ... to open// molecular pores, called ion channels, in the membrane ... Lu, MD, PhD; Yajamana Ramu, PhD; and Yanping Xu, MD, ... venoms from over 100 poisonous invertebrate species to make this ...
    ... today launched a new vision correction technology, Zyoptix Aspheric, ... ,"There are 60 clinics all across India which use ... be upgraded to Zyoptix Aspherix which further reduces post ... and Lomb India Director-Surgical business Rajat Goel told reporters ...
    ... like corks to block oxygen flow to tumors, or to ... to a tumor is called embolization, and using gas bubbles ... promising is that the technique allows doctors to control exactly ... to surrounding tissue is minimal, said Joseph Bull, assistant professor ...
    ... by Dr. Adam Godzik at the Burnham Institute for ... understanding of information gathered// from the human genome project. ... a three year period, this consortium, under the name ... adequate support to scientists from Burnham and UCSD's Computer ...
    ... labs of Yale Goldman, MD, PhD, Director of the ... of Medicine,// and Erika Holzbaur, PhD, Professor of Physiology, ... show proteins that function as molecular motors are surprisingly ... cell. These observations could lead to better ways to ...
    ... Once a month osteoporisis drug and extra telephone support from ... among women for their drug treatment// than those who took ... issue of IJCP, the International Journal of Clinical Practice. ... part in the PERSIST study between January 2005 and January ...
    Cached Medicine News:Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2Health News:Researchers Use Bubbles in Cancer Treatment and Drug Delivery 2Health News:Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego 2Health News:Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases 2Health News:Women More Persistent with Monthly Osteoporosis Treatment 2
    ... The Stryker Cross-Screw System ... and secure method for ACL ... The Stryker Cross-Screw System provides ... fixation. The implant comes in ...
    ... Universal Wedge Screw is a ... cruciate reconstruction and is indicated ... grafts. The Universal Wedge Screw ... has blunt threads which protect ...
    ... The Stryker Threaded ... surgeon yet another choice ... tunnel. Dilators provide compaction ... The compaction of bone ...
    ... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
    Medicine Products: